IACH Journal Club – Video Library

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
Prof. Graham Jackson, Prof. Francesca Gay
May 17, 2022

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapy
Prof. Melody Smith, Prof. Florent Malard
April 21, 2022

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
Prof. Roni Shouval, Prof. Nicola Polverelli
March 29, 2022

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Prof. Ibrahim Yakoub-Agha, Prof. Naveen Pemmaraju
Mar. 8, 2022

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Prof. Luciano J. Costa, Prof. Francesca Gay
Feb. 8, 2022

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma
Prof. Hervé TILLY, Prof. Ali Bazarbachi
Jan. 25, 2022

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft- Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
Prof. Miguel-Angel Perales, Prof. Didier Blaise
Jan. 4, 2022

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Prof. Thierry Facon and Prof. Mchel Delforge
Nov. 23, 2021

IACH Journal Club: Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission
Prof. Anna Sureda and Prof. Mehdi Hamadani
October 18, 2021

IACH Journal Club: CD19 Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Prof. Raffaella Greco and Prof. Andrea Bacigalupo
October 6, 2021

IACH Journal Club: Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Prof. Nizar J. Bahlis, Dr Cyrille Touzeau
September 21, 2021

IACH Journal Club: HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Prof. Mary Eapen, Prof. Arnon Nagler
September 7, 2021

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Dr. Shambavi Richard, Dr. Salomon Mainer
July 20, 2021

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia
Prof. Stephen A. Strickland, Prof. Thomas Cluzeau
July 6, 2021

 
Alex Lazaryan, Prof. Bipin Savani
June 24, 2021

 
Dr. Amanda Olson, Dr. Annalisa Ruggeri
June 8, 2021

 
Prof. Graham Jackson, Prof. Jean luc Harousseau
May 25, 2021

 
Prof. Elie Azoulay, Prof. Olalekan Oluwole
May 11, 2021

 
Prof. Anna Sureda, Dr. Reid Merryman
April 26, 2021

 
Dr. Adi Nagler, Prof. Martin Larsen
April 13, 2021

 
Dr. Jonathan Peled, Dr. Florent Malard
March 30, 2021

 
Prof. Peter Bader, Prof. Arnon Nagler
March 9, 2021

 
Dr. Nizar Bahlis and Dr. Salomon Manier
February 9, 2021

 
Prof. Pau Montesinos and Prof. Thomas Prebet
January 26, 2021

 
Prof. Marcelo C. Pasquini and Prof. Christian Chabannon
December 3rd, 2020

 
Prof. Steven Le Gouill and Prof. Christian Gisselbrecht
November 19, 2020

 
Prof. Robin Foà and Dr. Eolia Brissot
November 2, 2020

 
Prof. María-Victoria Mateos and Prof. Karthik Ramasamy
October 20, 2020

 
Prof. Mohamad Mohty
October 15, 2020

The Journal Club Meetings are supported in part by an unrestricted grant provided by the following supporters: